Contains Nonbinding Recommendations

Draft Guidance on Ertugliflozin

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Ertugliflozin

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 15 mg
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: None

---

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 15 mg
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: None

Analytes to measure (in appropriate biological fluid): Ertugliflozin in plasma

Bioequivalence based on (90% CI): Ertugliflozin

Waiver request of in vivo testing: 5 mg based on (i) acceptable BE studies on the 15 mg strength, (ii) comparable dissolution testing on both strengths, and (iii) proportional similarity in the formulations of both strengths.

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).